| 1 Leaving the study early: 1. Any reason |
1 |
40 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |
| 1.1 short term |
1 |
40 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |
| 2 Global state: 1. Change over time ‐ no better or deterioration (ITT) |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 2.1 short term |
1 |
40 |
Risk Ratio (M‐H, Random, 95% CI) |
2.5 [0.94, 6.66] |
| 3 Adverse events: Movement disorders |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 3.1 use of antiparkinsonian drugs ‐ short term |
1 |
40 |
Risk Ratio (M‐H, Random, 95% CI) |
0.8 [0.40, 1.60] |
| 4 Other adverse events: 1. Arousal |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 4.1 need of additional benzodiazepines ‐ short term |
1 |
40 |
Risk Ratio (M‐H, Random, 95% CI) |
1.1 [0.61, 1.99] |
